Streetbeat News

Products Services

VCNX

Vaccinex, Inc. (NASDAQ:VCNX), a biotech company, announced entering into eight new antibody discovery agreements using its ActivMAb platform for challenging transmembrane protein targets. These agreements include partnerships with major pharma and biotech companies as well as other antibody service providers. The ActivMAb platform, particularly its 'Antigen Virus' application, is highlighted for its efficiency in selecting antibodies against complex protein targets, which is crucial for developing therapeutics for diseases like cancer and Alzheimer's.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:21 pm

MTCH

Match Group has partnered with OpenAI to secure over 1000 ChatGPT Enterprise licenses for its employees, aiming to enhance productivity and innovation within its operations. This collaboration is expected to revolutionize work culture at Match Group by integrating AI into various aspects of work, from communications to coding. The company emphasizes responsible use of AI, ensuring privacy and security measures are in place.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:17 pm

AAPL

META

MSFT

SPOT

SSNLF

George Hotz, known for his iPhone jailbreaks, has switched from Apple's iPhone to Samsung's Galaxy Z Fold 5 due to dissatisfaction with Apple's App Store policies in the EU. Hotz criticized Apple for its handling of progressive web apps (PWA) and its 'tantrum' over app sideloading and alternative payment methods. This criticism aligns with concerns from other tech leaders, including Spotify's CEO Daniel Ek, Epic Games' CEO Tim Sweeney, Meta's Mark Zuckerberg, and Microsoft's Xbox President Sarah Bond, over Apple's App Store practices.

Portfolio Pulse from Rounak Jain

February 21, 2024 | 1:17 pm

MRVI

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (NASDAQ:MRVI), has secured patents in China and Canada for its CleanCap® Capping Technology, crucial for mRNA-based therapeutics and vaccines production. These patents add to the global IP portfolio, with CleanCap® already patented in major markets including the US and EU. The technology enhances mRNA production efficiency and has been used in COVID-19 vaccines. TriLink's CleanCap® M6 analog, launched last May, promises to further reduce manufacturing times and costs while increasing protein expression and mRNA yields.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:14 pm

HCAT

Health Catalyst, Inc. (NASDAQ:HCAT) announced that its MeasureAble application has achieved ONC Health IT 2015 Edition certification through Drummond Group LLC. This certification allows eligible providers and hospitals to use MeasureAble for various quality reporting programs, leveraging certified EHR technology. MeasureAble offers over 240 regulatory measures and combines data, calculations, and visualizations in one application, aiming to support healthcare transformation and performance improvement.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:12 pm

JOBY

Joby has successfully completed the third of five stages in the FAA type certification process, becoming the first eVTOL company to achieve this milestone towards commercialization.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:10 pm

PM

Philip Morris International Inc. (PMI) reaffirmed its FY24 EPS forecast at the 2024 CAGNY Conference, projecting a 7%-9% currency-neutral growth. The presentation highlighted PMI's transition towards a smoke-free business, integration with Swedish Match, and strong financial performance. The forecast anticipates a reported diluted EPS of $5.90-$6.02 and an adjusted diluted EPS of $6.32-$6.44, aligning with consensus expectations.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:09 pm

ASST

Asset Entities has launched a new Stripe-verified payment processing platform named Ternary Digital Community. This platform is designed to enhance digital payment solutions.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:08 pm

HRMY

Harmony Biosciences announced that the FDA has granted priority review for its supplemental New Drug Application (sNDA) for WAKIX, aimed at expanding its use. This development could significantly impact Harmony Biosciences' market position and future revenue streams, as priority review can expedite the drug's approval process.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:07 pm

ENSC

Ensysce Biosciences received guidance from the FDA on its PF614-MPAR program for severe pain treatment. The feedback focuses on non-clinical studies needed for NDA submission and approval, aiming to expedite the drug's market entry.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:06 pm